Rheumatic manifestations of inflammatory bowel disease.
This article reviews the literature concerning rheumatic manifestations of inflammatory bowel disease (IBD), including common immune-mediated pathways, frequency, clinical course and therapy. Musculoskeletal complications are frequent and well-recognized manifestations in IBD, and affect up to 33% of patients with IBD. The strong link between the bowel and the osteo-articular system is suggested by many clinical and experimental observations, notably in HLA-B27 transgenic rats. The autoimmune pathogenic mechanisms shared by IBD and spondyloarthropathies include genetic susceptibility to abnormal antigen presentation, aberrant recognition of self, the presence of autoantibodies against specific antigens shared by the colon and other extra-colonic tissues, and increased intestinal permeability. The response against microorganisms may have an important role through molecular mimicry and other mechanisms. Rheumatic manifestations of IBD have been divided into peripheral arthritis, and axial involvement, including sacroiliitis, with or without spondylitis, similar to idiopathic ankylosing spondylitis. Other periarticular features can occur, including enthesopathy, tendonitis, clubbing, periostitis, and granulomatous lesions of joints and bones. Osteoporosis and osteomalacia secondary to IBD and iatrogenic complications can also occur. The management of the rheumatic manifestations of IBD consists of physical therapy in combination with local injection of corticosteroids and nonsteroidal anti-inflammatory drugs; caution is in order however, because of their possible harmful effects on intestinal integrity, permeability, and even on gut inflammation. Sulfasalazine, methotrexate, azathioprine, cyclosporine and leflunomide should be used for selected indications. In some cases, tumor necrosis factor-alpha blocking agents should be considered as first-line therapy.
Rodríguez-Reyna
Tatiana Sofía
TS
Department of Immunology and Rheumatology, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Vasco de Quiroga 15, Col Sección XVI, Del, Tlalpan, Mexico City, Mexico.
Martínez-Reyes
Cynthia
C
Yamamoto-Furusho
Jesús Kazúo
JK
D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D015820:Cadherins / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D005762:Gastroenterology / Q000379:methods; D006801:Humans; D007249:Inflammation; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000175:diagnosis*; D007422:Intestines / Q000473:pathology; D019804:Mesalamine / Q000494:pharmacology; D010539:Permeability; D012216:Rheumatic Diseases / Q000150:complications / Q000175:diagnosis*; D013166:Spondylitis / Q000175:diagnosis / Q000473:pathology; D012460:Sulfasalazine / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D015820:Cadherins; D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha; D012460:Sulfasalazine; D019804:Mesalamine